First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis | PLOS ONE
![First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases | BMC Pregnancy and Childbirth | Full Text First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases | BMC Pregnancy and Childbirth | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12884-020-2789-2/MediaObjects/12884_2020_2789_Fig1_HTML.png)
First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases | BMC Pregnancy and Childbirth | Full Text
![First trimester PAPP-A serum levels and long-term metabolic outcome of mothers and their offspring | Scientific Reports First trimester PAPP-A serum levels and long-term metabolic outcome of mothers and their offspring | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-61830-5/MediaObjects/41598_2020_61830_Fig1_HTML.png)
First trimester PAPP-A serum levels and long-term metabolic outcome of mothers and their offspring | Scientific Reports
![Frontiers | Predictive Performance of Serum β-hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis Frontiers | Predictive Performance of Serum β-hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis](https://www.frontiersin.org/files/Articles/619530/fendo-12-619530-HTML-r1/image_m/fendo-12-619530-g001.jpg)
Frontiers | Predictive Performance of Serum β-hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis
![Table 3 from The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy. | Semantic Scholar Table 3 from The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/df64feabd4c7afce8285ca4067ceaa0fef4aeb8e/5-Table3-1.png)
Table 3 from The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy. | Semantic Scholar
![Frontiers | Trends in Non-invasive Prenatal Screening and Invasive Testing in Denmark (2000–2019) and Israel (2011–2019) Frontiers | Trends in Non-invasive Prenatal Screening and Invasive Testing in Denmark (2000–2019) and Israel (2011–2019)](https://www.frontiersin.org/files/Articles/768997/fmed-08-768997-HTML/image_m/fmed-08-768997-g001.jpg)
Frontiers | Trends in Non-invasive Prenatal Screening and Invasive Testing in Denmark (2000–2019) and Israel (2011–2019)
![PDF] Prenatal screening for fetal aneuploidies during the first and second trimester of pregnancy | Semantic Scholar PDF] Prenatal screening for fetal aneuploidies during the first and second trimester of pregnancy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4f76bec23cb327e170d0c2b42982fa27e318e43d/6-Table3-1.png)
PDF] Prenatal screening for fetal aneuploidies during the first and second trimester of pregnancy | Semantic Scholar
![PDF) Maternal weight correction of maternal serum PAPP-A and free ?-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy | Kevin Spencer - Academia.edu PDF) Maternal weight correction of maternal serum PAPP-A and free ?-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy | Kevin Spencer - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/42544380/mini_magick20190217-2520-1khgckc.png?1550437469)